Literature DB >> 9155856

Nebulised antibiotics for adults with cystic fibrosis.

A K Webb1, M E Dodd.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9155856      PMCID： PMC1765859          DOI： 10.1136/thx.52.2008.s69

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  19 in total

1.  Aminoglycoside ototoxicity in cystic fibrosis. Evaluation by high-frequency audiometry.

Authors:  T I McRorie; J Bosso; L Randolph
Journal:  Am J Dis Child       Date:  1989-11

2.  Comparison of nebulised aerosol deposition in the lungs of healthy adults following oral and nasal inhalation.

Authors:  M L Everard; J G Hardy; A D Milner
Journal:  Thorax       Date:  1993-10       Impact factor: 9.139

Review 3.  Aerosol antibiotic treatment in cystic fibrosis.

Authors:  J M Littlewood; S W Smye; H Cunliffe
Journal:  Arch Dis Child       Date:  1993-06       Impact factor: 3.791

4.  Nebulized colistin causes chest tightness in adults with cystic fibrosis.

Authors:  J Maddison; M Dodd; A K Webb
Journal:  Respir Med       Date:  1994-02       Impact factor: 3.415

5.  Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis.

Authors:  A L Smith; B W Ramsey; D L Hedges; B Hack; J Williams-Warren; A Weber; E J Gore; G J Redding
Journal:  Pediatr Pulmonol       Date:  1989

6.  Case-control and vector studies of nosocomial acquisition of Pseudomonas cepacia in adult patients with cystic fibrosis.

Authors:  D R Burdge; E M Nakielna; M A Noble
Journal:  Infect Control Hosp Epidemiol       Date:  1993-03       Impact factor: 3.254

7.  Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

Authors:  B W Ramsey; H L Dorkin; J D Eisenberg; R L Gibson; I R Harwood; R M Kravitz; D V Schidlow; R W Wilmott; S J Astley; M A McBurnie
Journal:  N Engl J Med       Date:  1993-06-17       Impact factor: 91.245

8.  Lung distribution and pharmacokinetics of aerosolized tobramycin.

Authors:  P Le Conte; G Potel; P Peltier; D Horeau; J Caillon; M E Juvin; M F Kerguéris; D Bugnon; D Baron
Journal:  Am Rev Respir Dis       Date:  1993-05

9.  Clinical features of Pseudomonas cepacia pneumonia in an epidemic among immunocompromised patients.

Authors:  Y Yamagishi; J Fujita; K Takigawa; K Negayama; T Nakazawa; J Takahara
Journal:  Chest       Date:  1993-06       Impact factor: 9.410

10.  Cystic fibrosis: antibiotic prescribing practices in the United Kingdom and Eire.

Authors:  R F Taylor; M E Hodson
Journal:  Respir Med       Date:  1993-10       Impact factor: 3.415
View more
  3 in total

Review 1.  The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?

Authors:  D Banerjee; D Stableforth
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

2.  Comparative efficacy of two doses of nebulized colistimethate in the eradication of Pseudomonas aeruginosa in children with cystic fibrosis.

Authors:  Marie-Sophie Brochet; Anne-Cathrine McDuff; Jean-François Bussières; Elaine Caron; Geneviève Fortin; Denis Lebel; Jacques-Edouard Marcotte
Journal:  Can Respir J       Date:  2007 Nov-Dec       Impact factor: 2.409

3.  Investigating the Temporal Relationships between Symptoms and Nebuliser Adherence in People with Cystic Fibrosis: A Series of N-of-1 Observations.

Authors:  Rosie Martin; Madelynne Arden; Jenny Porritt; Martin Wildman; Felix Naughton
Journal:  Healthcare (Basel)       Date:  2020-01-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.